Hims & Hers Health (HIMS) has experienced a significant decline of 75.50% from its May 2025 peak of $64.65, primarily attributed to a February 2026 lawsuit filed by Novo Nordisk alleging unlawful marketing practices related to unapproved semaglutide formulations. The legal challenge has weighed heavily on investor sentiment, dragging the telehealth company's share price down substantially from recent highs. Despite the sharp correction, Wall Street analysts maintain a constructive outlook on the stock's recovery potential, with an average 12-month price target of $39.32 implying approximately 150% upside from current levels.
The company is positioned to report record quarterly revenue of $619 million on February 23, underscoring underlying business momentum amid the legal headwinds. Technical indicators suggest the stock may be oversold, with a relative strength index (RSI) reading of 16.87 indicating potential conditions for a near-term rebound. Industry observers point to the temporary nature of GLP-1 marketing constraints relative to the company's broader growth trajectory.
Beyond the semaglutide controversy, Hims maintains diversified revenue streams across telehealth services, hair loss treatments, and sexual health supplements, each demonstrating robust expansion prospects. These complementary segments provide earnings potential independent of any resolution surrounding the current litigation, offering investors multiple avenues for value creation as the company navigates near-term regulatory pressures.